

# Product Datasheet

## LANA2 Antibody (CM-A807) - BSA Free NB200-167

Unit Size: 0.1 ml

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

[www.novusbio.com](http://www.novusbio.com)



[technical@novusbio.com](mailto:technical@novusbio.com)

**Reviews: 1** **Publications: 14**

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:  
[www.novusbio.com/NB200-167](http://www.novusbio.com/NB200-167)

Updated 9/9/2025 v.20.1

Earn rewards for product  
reviews and publications.

Submit a publication at [www.novusbio.com/publications](http://www.novusbio.com/publications)

Submit a review at [www.novusbio.com/reviews/destination/NB200-167](http://www.novusbio.com/reviews/destination/NB200-167)



**NB200-167**


LANA2 Antibody (CM-A807) - BSA Free

<b>Product Information</b>	
<b>Unit Size</b>	0.1 ml
<b>Concentration</b>	2.0 mg/ml
<b>Storage</b>	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
<b>Clonality</b>	Monoclonal
<b>Clone</b>	CM-A807
<b>Preservative</b>	0.1% Sodium Azide
<b>Isotype</b>	IgG1 Kappa
<b>Purity</b>	Protein G purified
<b>Buffer</b>	PBS
<b>Product Description</b>	
<b>Description</b>	Novus Biologicals Knockout (KO) Validated Mouse LANA2 Antibody (CM-A807) - BSA Free (NB200-167) is a monoclonal antibody validated for use in IHC, WB, ELISA, ICC/IF and IP. Anti-LANA2 Antibody: Cited in 14 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
<b>Host</b>	Mouse
<b>Species</b>	Human, Mouse, Virus
<b>Reactivity Notes</b>	Reacts with viral LANA2 protein and shows no cross-reactivity to cellular proteins. Also reacts with human and mouse viral KSHV proteins.
<b>Specificity/Sensitivity</b>	This is specific for KSHV LANA2 (residues 143-310 epitope recognition).
<b>Immunogen</b>	Recombinant LANA2 fusion protein.
<b>Product Application Details</b>	
<b>Applications</b>	Western Blot, Immunohistochemistry-Paraffin, ELISA, Immunocytochemistry/Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Frozen, Immunoprecipitation, Knockout Validated
<b>Recommended Dilutions</b>	Western Blot 2-4 ug/ml, ELISA 1:100-1:2000, Immunohistochemistry 1:10-1:500, Immunocytochemistry/ Immunofluorescence 1:10-1:500, Immunoprecipitation 1:10-1:500, Immunohistochemistry-Paraffin 1:10-1:500, Immunohistochemistry-Frozen 1:10-1:500, Knockout Validated reported in scientific literature (Golas et al)
<b>Application Notes</b>	By Western Blot, this antibody recognizes a viral protein in KSHV infected B-cells (~66-70 kDa).




## Images


Western Blot: LANA2 Antibody (CM-A807) [NB200-167] - Detection of LANA2 in infected lysates (30 ug) using 2 ug/ml of NB 200-167. ECL detection 1.5 minutes. Lane 1: BCBL-1 (KSHV+) Lane 2: BC-1 (KSHV+/EBV+) Lane 3: BCP-1 (KSHV+)



Immunohistochemistry-Paraffin: LANA2 Antibody (CM-A807) [NB200-167] - vIRF3 expression in KS tissues. We obtained KS tissue microarrays from AIDS Cancer Specimen Resource and performed immunohistochemistry, visualized by Aperio F.L. digital pathological scanning. A biopsy sample of KS TMA was stained with anti-LANA. Representative image shows the LANA staining of skin KS lesion. Image collected and cropped by CiteAb from the following publication (<https://mbio.asm.org/lookup/doi/10.1128/mBio.02217-17>), licensed under a CC-BY license.



Immunohistochemistry: LANA2 Antibody (CM-A807) - BSA Free [NB200-167] - vIRF3 expression in KS tissues. We obtained KS tissue microarrays from AIDS Cancer Specimen Resource & performed immunohistochemistry, visualized by Aperio F.L. digital pathological scanning. A biopsy sample of KS TMA was stained with anti-LANA & anti-vIRF3 (CM-A807). Representative images show the LANA staining of skin KS lesion & the vIRF3 staining of skin, tonsil, & mouth KS lesions & positive staining corresponding to either LANA or vIRF3 in total KS biopsy specimens embedded in TMA. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/29339432>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



## Publications

Okpara MO, Vaaltyn MC, Watson JL et al. Modulators of the Hop-HSP90 Protein-Protein Interaction Disrupt KSHV Lytic Replication. ACS infectious diseases 2024-10-30 [PMID: 39475219]

Choi UY, Lee JJ, Park A et al. Herpesvirus-induced spermidine synthesis and eIF5A hypusination for viral episomal maintenance Cell reports 2022-08-16 [PMID: 35977517] (WB, Human)

Golas G, Jang S, Naik N, et al. Comparative analysis of the viral interferon regulatory factors of KSHV for their requisite for virus production and inhibition of the type I interferon pathway Virology 2020-02-15 [PMID: 32056714]

Moodad S, El Hajj R, Hleihel R et al Lenalidomide in Combination with Arsenic Trioxide: an Effective Therapy for Primary Effusion Lymphoma Cancers (Basel) 2020-09-05 [PMID: 32883022] (WB)

### Details:

Citation using the HRP version of this antibody.

Chen J, Dai L, Goldstein A et al. Identification of new antiviral agents against Kaposi's sarcoma-associated herpesvirus (KSHV) by high-throughput drug screening reveals the role of histamine-related signaling in promoting viral lytic reactivation PLoS Pathog. 2019-12-01 [PMID: 31790497] (WB)

Xiang Q, Ju H, Li Q et al. Human Herpesvirus 8 Interferon Regulatory Factors 1 and 3 Mediate Replication and Latency Activities via Interactions with USP7 Deubiquitinase J. Virol. 2018-01-17 [PMID: 29343584] (WB)

Lee HR, Li F, Choi UY et al. Deregulation of HDAC5 by Viral Interferon Regulatory Factor 3 Plays an Essential Role in Kaposi's Sarcoma-Associated Herpesvirus-Induced Lymphangiogenesis MBio 2018-01-16 [PMID: 29339432] (Virus)

Sarek G, Jarviluoma A, Moore HM et al. Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency PLoS Pathog. 2010-03-19 [PMID: 20333249] (WB, Virus)

Liang Q, Chang B, Lee P et al. Identification of the essential role of vBcl2 for KSHV lytic replication J. Virol. 2015-03-04 [PMID: 25740994] (WB)

Zuo J, Hislop AD, Leung C et al. KSHV encoded vIRF3 modulates MHC-II antigen presentation through CIITA dependent and independent mechanisms: implications for oncogenesis. J Virol 2013-02-28 [PMID: 23449805] (WB, Human)

Marcos-Villar L, Gallego P, Munoz-Fontela C et al. Kaposi's sarcoma-associated herpesvirus lana2 protein interacts with the pocket proteins and inhibits their sumoylation. Oncogene 2013-01-14 [PMID: 23318443] (WB, Human)

Marcos-Villar L, Lopitz-Otsoa F, Gallego P et al. Kaposi's Sarcoma-Associated Herpesvirus Protein LANA2 Disrupts PML Oncogenic Domains Inhibits PML-Mediated Transcriptional Repression of the Survivin Gene. J Virol;83 (17):8849-8858. 2009-01-01 [PMID: 19553342]

More publications at <http://www.novusbio.com/NB200-167>

## Procedures

### Serum protocol for LANA2 Antibody (NB200-167)

#### Western Blot Protocol

1. Perform SDS-PAGE (4-12%) on samples to be analyzed, loading 30ug of total protein per lane.
2. Transfer proteins to Nitrocellulose according to the instructions provided by the manufacturer of the transfer apparatus.
3. Stain the blot using ponceau S for 1-2 minutes to access the transfer of proteins onto the nitrocellulose membrane. Rinse the blot in water to remove excess stain and mark the lane locations and locations of molecular weight markers using a pencil.
4. Rinse the blot in TBS for approximately 5 minutes.
5. Block the membrane using 5% non-fat dry milk in TBS for 1 hour.
6. Dilute the mouse anti-LANA2 primary antibody (NB 200-167) in blocking buffer and incubate 2 hours at room temperature.
7. Wash the membrane in water for 5 minutes and apply the diluted mouse-IgG HRP-conjugated secondary antibody in blocking buffer (as per manufacturers instructions) and incubate 1 hour at room temperature.
8. Wash the blot in TBS containing 0.05-0.1% Tween-20 for 10-20 minutes.
9. Wash the blot in type I water for an additional 10-20 minutes (this step can be repeated as required to reduce background).
10. Apply the detection reagent of choice in accordance with the manufacturers instructions (Amersham's ECL is the standard reagent used at Novus Biologicals).

Note: Tween-20 can be added to the blocking buffer at a final concentration of 0.05-0.2%, provided it does not interfere with antibody-antigen binding.





### **Novus Biologicals USA**

10730 E. Briarwood Avenue  
Centennial, CO 80112  
USA  
Phone: 303.730.1950  
Toll Free: 1.888.506.6887  
Fax: 303.730.1966  
nb-customerservice@bio-techne.com

### **Bio-Techne Canada**

21 Canmotor Ave  
Toronto, ON M8Z 4E6  
Canada  
Phone: 905.827.6400  
Toll Free: 855.668.8722  
Fax: 905.827.6402  
canada.inquires@bio-techne.com

### **Bio-Techne Ltd**

19 Barton Lane  
Abingdon Science Park  
Abingdon, OX14 3NB, United Kingdom  
Phone: (44) (0) 1235 529449  
Free Phone: 0800 37 34 15  
Fax: (44) (0) 1235 533420  
info.EMEA@bio-techne.com

### **General Contact Information**

www.novusbio.com  
Technical Support: nb-technical@bio-techne.com  
Orders: nb-customerservice@bio-techne.com  
General: novus@novusbio.com

### **Products Related to NB200-167**

---

NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF007	Goat anti-Mouse IgG Secondary Antibody [HRP]
NB7539	Goat anti-Mouse IgG (H+L) Secondary Antibody [HRP]
NBP1-43319-0.5mg	Mouse IgG1 Kappa Isotype Control (P3.6.2.8.1)

---

### **Limitations**

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit [www.novusbio.com/guarantee](http://www.novusbio.com/guarantee)

Earn gift cards/discounts by submitting a review: [www.novusbio.com/reviews/submit/NB200-167](http://www.novusbio.com/reviews/submit/NB200-167)

Earn gift cards/discounts by submitting a publication using this product:  
[www.novusbio.com/publications](http://www.novusbio.com/publications)

